-
2
-
-
0024852022
-
Ascertaining the minimal clinically important difference
-
R. Jaeschke, J. Singer, and G.H. Guyatt Ascertaining the minimal clinically important difference Cont Clin Trials 10 1989 407 415
-
(1989)
Cont Clin Trials
, vol.10
, pp. 407-415
-
-
Jaeschke, R.1
Singer, J.2
Guyatt, G.H.3
-
3
-
-
84655169696
-
Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials
-
K. Reich, A.D. Burden, J.N. Eaton, and N.S. Hawkins Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials Br J Dermatol 166 2012 179 188
-
(2012)
Br J Dermatol
, vol.166
, pp. 179-188
-
-
Reich, K.1
Burden, A.D.2
Eaton, J.N.3
Hawkins, N.S.4
-
4
-
-
84867582191
-
Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment
-
T.C. Lucka, D. Pathirana, A. Sammain, F. Bachmann, S. Rosumeck, and R. Erdmann et al. Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment J Eur Acad Dermatol Venereol 26 2012 1331 1344
-
(2012)
J Eur Acad Dermatol Venereol
, vol.26
, pp. 1331-1344
-
-
Lucka, T.C.1
Pathirana, D.2
Sammain, A.3
Bachmann, F.4
Rosumeck, S.5
Erdmann, R.6
-
5
-
-
84871378386
-
Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: A bayesian network meta-analysis
-
V.W. Lin, S. Ringold, and E.B. Devine Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: A bayesian network meta-analysis Arch Dermatol 148 2012 1403 1410
-
(2012)
Arch Dermatol
, vol.148
, pp. 1403-1410
-
-
Lin, V.W.1
Ringold, S.2
Devine, E.B.3
-
6
-
-
0030793120
-
The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials
-
H.C. Bucher, G.H. Guyatt, L.E. Griffith, and S.D. Walter The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 50 1997 683 691
-
(1997)
J Clin Epidemiol
, vol.50
, pp. 683-691
-
-
Bucher, H.C.1
Guyatt, G.H.2
Griffith, L.E.3
Walter, S.D.4
-
7
-
-
70449517166
-
-
2013 Canadian Agency for Drugs and Technologies in Health. [acceso 12 Jul 2013]
-
Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis. © 2013 Canadian Agency for Drugs and Technologies in Health. [acceso 12 Jul 2013]. Disponible en: http://www.cadth.ca/en/products/methods-and-guidelines/ publication/884
-
Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis
-
-
-
9
-
-
84879994854
-
Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis
-
S. Fénix-Caballero, E.J. Alegre-del Rey, R. Castaño-Lara, F. Puigventós-Latorre, J.M. Borrero-Rubio, and J.F. López-Vallejo Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis J Clin Pharm Ther 38 2013 286 293
-
(2013)
J Clin Pharm Ther
, vol.38
, pp. 286-293
-
-
Fénix-Caballero, S.1
Alegre-Del Rey, E.J.2
Castaño-Lara, R.3
Puigventós-Latorre, F.4
Borrero-Rubio, J.M.5
López-Vallejo, J.F.6
-
10
-
-
84880331409
-
Which antipsoriatic drug has the fastest onset of action?-Systematic review on the rapidity of the onset of action
-
A. Nast, B. Sporbeck, S. Rosumeck, D. Pathirana, A. Jacobs, and R.N. Werner et al. Which antipsoriatic drug has the fastest onset of action?-Systematic review on the rapidity of the onset of action J Invest Dermatol 133 2013 1963 1970
-
(2013)
J Invest Dermatol
, vol.133
, pp. 1963-1970
-
-
Nast, A.1
Sporbeck, B.2
Rosumeck, S.3
Pathirana, D.4
Jacobs, A.5
Werner, R.N.6
|